• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Are ACOs Ready to be Accountable for Medication Use?ACO 能否准备好为药物使用负责?
J Manag Care Spec Pharm. 2020 Nov;26(11):1446-1451. doi: 10.18553/jmcp.2020.26.11.1446.
2
Are ACOs ready to be accountable for medication use?负责医疗组织(ACO)是否准备好对药物使用负责?
J Manag Care Pharm. 2014 Jan;20(1):17-21. doi: 10.18553/jmcp.2014.20.1.17.
3
Optimization of Medication Use at Accountable Care Organizations.优化问责制医疗组织中的药物使用。
J Manag Care Spec Pharm. 2017 Oct;23(10):1054-1064. doi: 10.18553/jmcp.2017.23.10.1054.
4
The Central Role of Physician Leadership for Driving Change in Value-Based Care Environments.医师领导力在推动基于价值的医疗保健环境变革中的核心作用。
J Manag Care Spec Pharm. 2016 Oct;22(10):1116-22. doi: 10.18553/jmcp.2016.22.10.1116.
5
Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management.最佳实践:通过全面药物治疗管理改善 ACO 中的患者预后和成本。
J Manag Care Spec Pharm. 2014 Dec;20(12):1152-8.
6
Clinical and Economic Benefits of Pharmacist Involvement in a Community Hospital-Affiliated Patient-Centered Medical Home.临床和经济效益的药剂师参与社区医院相关的以患者为中心的医疗之家。
J Manag Care Spec Pharm. 2018 Feb;24(2):160-164. doi: 10.18553/jmcp.2018.24.2.160.
7
Integration Strategies of Pharmacists in Primary Care-Based Accountable Care Organizations: A Report from the Accountable Care Organization Research Network, Services, and Education.基于初级保健责任制医疗组织的药师整合策略:来自责任制医疗组织研究网络、服务和教育的报告。
J Manag Care Spec Pharm. 2017 May;23(5):541-548. doi: 10.18553/jmcp.2017.23.5.541.
8
Improving Oncology Quality Measurement in Accountable Care: Filling Gaps with Cross-Cutting Measures.提高责任医疗中的肿瘤学质量衡量标准:使用跨领域衡量标准填补空白。
J Manag Care Spec Pharm. 2017 Feb;23(2):174-181. doi: 10.18553/jmcp.2017.23.2.174.
9
Cardiologist Participation in Accountable Care Organizations and Changes in Spending and Quality for Medicare Patients With Cardiovascular Disease.心脏病专家参与负责医疗组织以及医疗保险心血管疾病患者的支出和质量变化
Circ Cardiovasc Qual Outcomes. 2019 Sep;12(9):e005438. doi: 10.1161/CIRCOUTCOMES.118.005438. Epub 2019 Sep 16.
10
Best Practices: Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management.最佳实践:通过全面药物治疗管理改善 ACO 中的患者预后和成本。
J Manag Care Spec Pharm. 2014 Dec;20(12):1152-8.

引用本文的文献

1
Impact of a commercial accountable care organization on prescription drugs.商业管理式医疗组织对处方药的影响。
Health Serv Res. 2021 Aug;56(4):592-603. doi: 10.1111/1475-6773.13626. Epub 2021 Jan 28.
2
Best practices: an electronic drug alert program to improve safety in an accountable care environment.最佳实践:在问责制医疗环境中,采用电子药品警报程序以提高安全性。
J Manag Care Spec Pharm. 2015 Apr;21(4):330-6. doi: 10.18553/jmcp.2015.21.4.330.

本文引用的文献

1
Role of pharmaceuticals in value-based healthcare: a framework for success.药品在基于价值的医疗保健中的作用:成功框架。
Am J Manag Care. 2012 Jul 1;18(7):1 p following e244.
2
Shared decision making--pinnacle of patient-centered care.共同决策——以患者为中心的医疗的巅峰。
N Engl J Med. 2012 Mar 1;366(9):780-1. doi: 10.1056/NEJMp1109283.
3
Progress toward meaningful use: hospitals' adoption of electronic health records.迈向有意义使用的进展:医院采用电子健康记录。
Am J Manag Care. 2011 Dec;17(12 Spec No.):SP117-24.
4
Patient engagement in health care.患者参与医疗保健。
Health Serv Res. 2011 Apr;46(2):389-93. doi: 10.1111/j.1475-6773.2011.01254.x.
5
Impact of generic substitution decision support on electronic prescribing behavior.药品通用名替代决策支持对电子处方行为的影响。
J Am Med Inform Assoc. 2010 Nov-Dec;17(6):681-8. doi: 10.1136/jamia.2009.002568.
6
US pharmacists' effect as team members on patient care: systematic review and meta-analyses.美国药剂师作为团队成员对患者护理的影响:系统评价和荟萃分析。
Med Care. 2010 Oct;48(10):923-33. doi: 10.1097/MLR.0b013e3181e57962.
7
The triple aim: care, health, and cost.三重目标:医疗、健康和成本。
Health Aff (Millwood). 2008 May-Jun;27(3):759-69. doi: 10.1377/hlthaff.27.3.759.
8
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.用通用名药物替代品牌名药物可能节省的费用:1997 - 2000年医疗支出小组调查
Ann Intern Med. 2005 Jun 7;142(11):891-7. doi: 10.7326/0003-4819-142-11-200506070-00006.
9
Reducing readmissions for congestive heart failure.降低充血性心力衰竭的再入院率。
Am Fam Physician. 2001 Apr 15;63(8):1593-8.

ACO 能否准备好为药物使用负责?

Are ACOs Ready to be Accountable for Medication Use?

机构信息

Chief Science Officer, Health Services Research, National Pharmaceutical Council, Washington, DC.

Senior Director, Medication Management, and Managing Principal, Pharmacy Consulting, Healthcare Innovators Collaborative, Premier Healthcare Alliance, Charlotte, North Carolina.

出版信息

J Manag Care Spec Pharm. 2020 Nov;26(11):1446-1451. doi: 10.18553/jmcp.2020.26.11.1446.

DOI:10.18553/jmcp.2020.26.11.1446
PMID:33119446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10390926/
Abstract

Accountable care organizations (ACOs) have the potential to lower costs and improve quality through incentives and coordinated care. However, the design brings with it many new challenges. One such challenge is the optimal use of pharmaceuticals. Most ACOs have not yet focused on this integral facet of care, even though medications are a critical component to achieving the lower costs and improved quality that are anticipated with this new model. To evaluate whether ACOs are prepared to maximize the value of medications for achieving quality benchmarks and cost offsets. During the fall of 2012, an electronic readiness self-assessment was developed using a portion of the questions and question methodology from the National Survey of Accountable Care Organizations, along with original questions developed by the authors. The assessment was tested and subsequently revised based on feedback from pilot testing with 5 ACO representatives. The revised assessment was distributed via e-mail to a convenience sample (n=175) of ACO members of the American Medical Group Association, Brookings-Dartmouth ACO Learning Network, and Premier Healthcare Alliance. The self-assessment was completed by 46 ACO representatives (26% response rate). ACOs reported high readiness to manage medications in a few areas, such as transmitting prescriptions electronically (70%), being able to integrate medical and pharmacy data into a single database (54%), and having a formulary in place that encourages generic use when appropriate (50%). However, many areas have substantial room for improvement with few ACOs reporting high readiness. Some notable areas include being able to quantify the cost offsets and hence demonstrate the value of appropriate medication use (7%), notifying a physician when a prescription has been filled (9%), having protocols in place to avoid medication duplication and polypharmacy (17%), and having quality metrics in place for a broad diversity of conditions (22%). Developing the capabilities to support, monitor, and ensure appropriate medication use will be critical to achieve optimal patient outcomes and ACO success. The ACOs surveyed have embarked upon an important journey towards this goal, but critical gaps remain before they can become fully accountable. While many of these organizations have begun adopting health information technologies that allow them to maximize the value of medications for achieving quality outcomes and cost offsets, a significant lag was identified in their inability to use these technologies to their full capacities. In order to provide further guidance, the authors have begun documenting case studies for public release that would provide ACOs with examples of how certain medication issues have been addressed by ACOs or relevant organizations. The authors hope that these case studies will help ACOs optimize the value of pharmaceuticals and achieve the "triple aim" of improving care, health, and cost. There was no outside funding for this study, and the authors report no conflicts of interest related to the article. Concept and design were primarily from Dubois and Kotzbauer, with help from Feldman, Penso, and Westrich. Data collection was done by Feldman, Penso, Pope, and Westrich, and all authors participated in data interpretation. The manuscript was written primarily by Westrich, with help from all other authors, and revision was done primarily by Lustig and Westrich, with help from all other authors.

摘要

责任医疗组织 (ACO) 通过激励措施和协调护理有降低成本和提高质量的潜力。然而,其设计带来了许多新的挑战。其中一个挑战是药品的最佳使用。大多数 ACO 尚未关注这一护理的基本方面,尽管药物是实现该新模式预期的更低成本和更高质量的关键组成部分。评估 ACO 是否准备好最大限度地发挥药物的价值,以实现质量基准和成本抵消。在 2012 年秋季,使用国家责任医疗组织调查的一部分问题和问题方法以及作者开发的原始问题,开发了电子准备情况自我评估。评估根据与 5 名 ACO 代表进行的试点测试的反馈进行了测试和随后的修订。修订后的评估通过电子邮件分发给美国医疗集团协会、布鲁金斯-达特茅斯 ACO 学习网络和 Premier Healthcare Alliance 的 ACO 成员便利样本(n=175)。自我评估由 46 名 ACO 代表完成(26%的回复率)。ACO 报告在一些领域管理药物的准备情况很高,例如电子传输处方(70%)、能够将医疗和药房数据集成到单个数据库中(54%)以及拥有鼓励在适当情况下使用通用药物的处方集(50%)。然而,许多领域有很大的改进空间,很少有 ACO 报告准备情况良好。一些值得注意的领域包括能够量化成本抵消,从而证明适当药物使用的价值(7%)、在处方已填写时通知医生(9%)、制定协议以避免药物重复使用和多种药物治疗(17%)以及为广泛的各种疾病制定质量指标(22%)。开发支持、监测和确保适当药物使用的能力对于实现最佳患者结果和 ACO 成功至关重要。接受调查的 ACO 已经朝着这个目标迈出了重要的一步,但在他们能够完全负责之前,仍然存在关键差距。虽然许多这些组织已经开始采用允许他们最大限度地发挥药物价值以实现质量结果和成本抵消的健康信息技术,但在他们无法充分利用这些技术方面存在重大差距。为了提供进一步的指导,作者已开始记录公开发布的案例研究,为 ACO 提供有关如何解决特定药物问题的示例,这些问题已由 ACO 或相关组织解决。作者希望这些案例研究将帮助 ACO 优化药品的价值,并实现改善护理、健康和成本的“三重目标”。这项研究没有外部资金,作者与文章没有利益冲突。概念和设计主要来自杜波依斯和科茨鲍尔,费尔德曼、彭索、韦斯特里奇提供了帮助。数据收集由费尔德曼、彭索、波普和韦斯特里奇完成,所有作者都参与了数据解释。手稿主要由韦斯特里奇撰写,其他作者提供了帮助,卢斯蒂格和韦斯特里奇主要负责修改,其他作者也提供了帮助。